Skip to main content

IDWeek 2022 Main banner

Tweets by IDWeek 2022

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

449 Views

Poster Session: Adult Vaccines

120 - Safety, Reactogenicity, and Immunogenicity of Three Different Doses of VAC52416 (ExPEC10V) in Adults Aged 60–85 Years in a Randomized, Multicenter, Interventional, First-In-Human, Phase 1/2a Study

Thursday, October 20, 2022

12:15 PM – 1:30 PM US ET

Location: Hall B + C

The ePoster content is available to users who are logged in.<br><br>Please click the login button at the top right corner and then come back here to use this button.

Co-Author(s)

JD

Joachim Doua, MD, MPH

Janssen Research & Development, Infectious Diseases & Vaccines, Janssen Pharmaceutica
Beerse, Antwerpen, Belgium
CF

Carlos Fierro, MD

Investigator
Johnson County Clin-Trials
Lenexa, Kansas, United States

Presenting Author(s)

Michal Sarnecki, MD

Medical Leader VX Bern Clin
Janssen Research & Development, Janssen Vaccines
Bern, Bern, Switzerland

Co-Author(s)

BS

Bart Spiessens, PhD

Senior Scientific Director Biostatistics
Janssen Research & Development, Infectious Diseases & Vaccines, Janssen Pharmaceutica
Beerse, Antwerpen, Belgium
OG

Oscar Go, PhD

Associate Director
Janssen Research & Development
Raritan, New Jersey, United States
TD

Todd Davies, PhD

Janssen Research & Development
Raritan, New Jersey, United States
Gv

Germie van den Dobbelsteen, PhD

Janssen Research & Development, Infectious Diseases & Vaccines, Janssen Pharmaceutica
Leiden, Zuid-Holland, Netherlands
JP

Jan Poolman, PhD

VP Bacterial Vaccines
Bacterial Vaccines Discovery and Early Development, Janssen Vaccines & Prevention B.V.
Leiden, Zuid-Holland, Netherlands
WH

Wouter Haazen, MD, MSc

Trial Physician
3Janssen Research & Development, Infectious Diseases & Vaccines, Janssen Pharmaceutica
Beerse, Antwerpen, Belgium